Changgui Li

8.6k total citations · 2 hit papers
99 papers, 2.9k citations indexed

About

Changgui Li is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Changgui Li has authored 99 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Epidemiology, 41 papers in Infectious Diseases and 19 papers in Immunology. Recurrent topics in Changgui Li's work include Influenza Virus Research Studies (39 papers), Respiratory viral infections research (39 papers) and SARS-CoV-2 and COVID-19 Research (24 papers). Changgui Li is often cited by papers focused on Influenza Virus Research Studies (39 papers), Respiratory viral infections research (39 papers) and SARS-CoV-2 and COVID-19 Research (24 papers). Changgui Li collaborates with scholars based in China, Canada and Saudi Arabia. Changgui Li's co-authors include Junzhi Wang, Xuguang Li, Fengcai Zhu, Hongxing Pan, Kai Chu, Yuansheng Hu, Weidong Yin, Qiang Gao, Weixiao Han and Rong Tang and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Changgui Li

97 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

2020 937 citations Hongxing Pan, Changgui Li et al. profile →
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

2021 211 citations Changgui Li, Zhiwei Jiang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Changgui Li China	23	1.7k	1.3k	540	520	447	99	2.9k
Joanna Ellis United Kingdom	38	1.7k 1.0×	3.3k 2.6×	488 0.9×	400 0.8×	573 1.3×	115	4.8k
Fatima Amanat United States	27	2.8k 1.6×	1.0k 0.8×	263 0.5×	640 1.2×	531 1.2×	55	3.8k
Miao Xu China	25	2.1k 1.2×	389 0.3×	297 0.6×	416 0.8×	674 1.5×	68	2.9k
Ralf Clemens Germany	39	2.0k 1.1×	2.3k 1.8×	477 0.9×	692 1.3×	503 1.1×	140	4.9k
Emma C. Thomson United Kingdom	22	2.9k 1.7×	828 0.7×	196 0.4×	284 0.5×	938 2.1×	90	4.0k
Joseph Torresi Australia	43	1.6k 0.9×	2.2k 1.8×	190 0.4×	396 0.8×	447 1.0×	145	5.4k
Chris Ka Pun Mok Hong Kong	28	2.3k 1.3×	1.1k 0.9×	136 0.3×	621 1.2×	647 1.4×	87	3.3k
A.M. Palache Netherlands	33	818 0.5×	2.7k 2.1×	420 0.8×	1.1k 2.2×	453 1.0×	59	3.4k
Nathalie Bastien Canada	43	2.6k 1.5×	3.4k 2.7×	254 0.5×	429 0.8×	773 1.7×	104	5.5k
Deborah Cromer Australia	25	2.9k 1.7×	597 0.5×	538 1.0×	624 1.2×	520 1.2×	70	4.0k

Countries citing papers authored by Changgui Li

Since Specialization

Citations

This map shows the geographic impact of Changgui Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changgui Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changgui Li more than expected).

Fields of papers citing papers by Changgui Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changgui Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changgui Li. The network helps show where Changgui Li may publish in the future.

Co-authorship network of co-authors of Changgui Li

This figure shows the co-authorship network connecting the top 25 collaborators of Changgui Li. A scholar is included among the top collaborators of Changgui Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changgui Li. Changgui Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Song, Yanli, Zhihui Yang, Ying Xie, et al.. (2024). Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency. Frontiers in Immunology. 15. 1406138–1406138. 6 indexed citations

Ма, Лей, Wei Cai, Jianfeng Wang, et al.. (2023). Immune persistence of an inactivated poliovirus vaccine derived from the Sabin strain: a 10-year follow-up of a phase 3 study. EClinicalMedicine. 64. 102151–102151. 3 indexed citations

Jiang, Deyu, Weixiao Han, Zhiqiang Xie, et al.. (2023). Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. International Journal of Infectious Diseases. 130. 20–27. 2 indexed citations

Xie, Ying, et al.. (2023). Understanding the mechanisms for COVID-19 vaccine’s protection against infection and severe disease. Expert Review of Vaccines. 22(1). 186–192. 8 indexed citations

Huang, Lirong, Lingyun Zhou, Li Shi, et al.. (2023). Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial. Vaccine. 41(19). 3141–3149. 7 indexed citations

Hu, Yuemei, Kangwei Xu, Weixiao Han, et al.. (2019). Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China. Open Forum Infectious Diseases. 6(10). 8 indexed citations

Russell, Marsha S., Caroline Gravel, Changgui Li, et al.. (2018). Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection. Scientific Reports. 8(1). 16648–16648. 6 indexed citations

Chu, Kai, Ling Wang, Yuansheng Hu, et al.. (2018). Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 36(45). 6782–6789. 20 indexed citations

Ning, Tingting, Jianhui Nie, Weijin Huang, et al.. (2018). Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin. The Journal of Infectious Diseases. 219(1). 19–25. 28 indexed citations

10.

Xu, Kangwei, Changgui Li, Caroline Gravel, et al.. (2018). Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines. Scientific Reports. 8(1). 1067–1067. 6 indexed citations

11.

Fortin, Nathalie, Junzhi Wang, Changgui Li, et al.. (2017). Fast and highly selective determination of hemagglutinin content in quadrivalent influenza vaccine by reversed-phase high-performance liquid chromatography method. Journal of Chromatography A. 1528. 18–24. 6 indexed citations

12.

Wu, Ting, Yuemei Hu, Juan Li, et al.. (2015). Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 33(32). 3940–3946. 21 indexed citations

13.

Zheng, Dan, Changgui Li, Wenjie Zhang, et al.. (2015). Protection against Multiple Subtypes of Influenza Viruses by Virus-Like Particle Vaccines Based on a Hemagglutinin Conserved Epitope. BioMed Research International. 2015. 1–12. 33 indexed citations

14.

Xu, Kangwei, Ming Shao, Shuzhen Liu, et al.. (2014). Rapid preparation of antiserum against influenza virus (H7N9) hemagglutinin for single radial immunodiffusion assay. Zhonghua weishengwuxue he mianyixue zazhi. 34(2). 146–148. 3 indexed citations

15.

Wang, Shilei, Wei Li, Changgui Li, et al.. (2012). The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study. PubMed. 2. 184–189. 4 indexed citations

16.

Hashem, Anwar M., Tracey M. Doyle, Gary Van Domselaar, et al.. (2011). Recent Developments in Bioinformatics Analyses of Influenza A Virus Surface Glycoproteins and their Biological Relevance. Current Bioinformatics. 6(4). 415–426. 11 indexed citations

17.

Liu, Ze, et al.. (2010). Screening of a high growth influenza B virus strain in Vero cells. Virologica Sinica. 25(1). 65–70. 5 indexed citations

18.

Li, Changgui, Ming Shao, Xiaoyu Cui, et al.. (2010). Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals. 38(2). 284–289. 34 indexed citations

19.

Zhu, Fengcai, Hua Wang, Han-hua Fang, et al.. (2009). A Novel Influenza A (H1N1) Vaccine in Various Age Groups. New England Journal of Medicine. 361(25). 2414–2423. 289 indexed citations

20.

Chen, Weijun, Bo He, Changgui Li, et al.. (2007). Real-time RT-PCR for H5N1 avian influenza A virus detection. Journal of Medical Microbiology. 56(5). 603–607. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact